Halozyme prices upsized $1.3B convertible senior notes due 2033

Corporate Action
โดย Seeking Alpha·US·Read original
Summary · why it matters

Halozyme Therapeutics announced on Thursday the pricing of $1.3B aggregate principal amount of 1.50% convertible senior notes due 2033, an increase from the previously announced offering size of $1.05B aggregate principal amount. The company also granted the initial purchasers a 13-day option to buy up to an additional $200M aggregate principal amount of the convertible notes. Shares of Halozyme rose 1.3% in post market trading.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
Halozyme Therapeutics Inc
HALO
▲ PositiveCapitalrelevance

Halozyme upsized its convertible senior notes offering to $1.3B, a financing event that strengthens its balance sheet.

© 2026 MarketDXNews